drugset / Trial / NCT07698899
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
Timeline
- Start
- 2026-07-02
- Primary completion
- 2030-06-02
- Completion
- 2030-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DTPA-omburtamab | Monoclonal antibody | 925 mbq | — |
| Subject | 177Lu-DTPA-omburtamab | Monoclonal antibody | 1850 mbq | — |
| Subject | 177Lu-DTPA-omburtamab | Monoclonal antibody | 2775 mbq | — |
| Subject | 177Lu-DTPA-omburtamab | Monoclonal antibody | 3700 mbq | — |